Enzaplatovir (Synonyms: BTA-C585) |
Catalog No.GC62955 |
Enzaplatovir(BTA-C585)는 호흡기 세포융합 바이러스(RSV) 감염에 대한 경구 생체이용 융합 억제제입니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1323077-89-9
Sample solution is provided at 25 µL, 10mM.
Enzaplatovir (BTA-C585) is an orally bioavailable fusion inhibitor for respiratory syncytial virus (RSV) infection[1].
Respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) imposes a substantial medical burden. Enzaplatovir is a small-molecule RSV entry inhibitor[1].
[1]. Eric A F SimÕes, et al. Past, Present and Future Approaches to the Prevention and Treatment of Respiratory Syncytial Virus Infection in Children. Infect Dis Ther. 2018 Mar;7(1):87-120.
Average Rating: 5
(Based on Reviews and 15 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *